Question 1

Does UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS own VIVO stock?

Accepted Answer

No. UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS exited its VIVO (Meridian Bioscience) position in Q4 2022. Its Q3 2022 13F listed 53,786 shares worth $1.7M.

Question 2

How many shares of VIVO does UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS own?

Accepted Answer

None since Q4 2022, when UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS exited the position. Its Q3 2022 13F listed 53,786 shares worth $1.7M.

Question 3

What is UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS' VIVO position worth?

Accepted Answer

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS' VIVO position was worth $1.7M in its Q3 2022 13F, before the exit in Q4 2022.

Question 4

Is UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS buying or selling VIVO?

Accepted Answer

In Q4 2022, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS exited its entire VIVO position.

Question 5

When did UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS first buy VIVO?

Accepted Answer

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS already held VIVO in its Q4 2018 13F, the earliest on record, and listed it in 16 quarterly 13F filings.